MLTX — MOONLAKE IMMUNOTHERAPEUTICS

Ownership history in STEMPOINT CAPITAL LP  ·  4 quarters on record

This page tracks every 13F SEC filing in which STEMPOINT CAPITAL LP reported a position in MOONLAKE IMMUNOTHERAPEUTICS (MLTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.7% (2023 Q4)
Avg. % of fund
1.2%
First filed
2023 Q4
Last filed
2025 Q4
Quarters held
4
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 348,401 +257,754 +284.3% 0.79% $4.6M $13.18
2024 Q1 ADDED 90,647 +90,147 +18029.4% 1.20% $4.6M $50.23
2023 Q4 REDUCED 500 -167,351 -99.7% 0.09% $335K —
2023 Q4 INITIATED 167,851 — — 2.70% $10.1M —
% of Fund (quarterly)    MLTX price (monthly, adj. close)

Other funds also holding MLTX

As of 2025 Q4 — sorted by position size

BVF INC/IL 3Y 7Y 8.76% Lion Point Capital, LP 3Y 7Y 4.6% Cormorant Asset Management, LP 3Y 7Y 2.65% Logos Global Management LP 3Y 1.39% Deep Track Capital, LP 3Y 1.08% Vivo Capital, LLC 3Y 7Y 0.85% Eagle Health Investments LP 3Y 0.54% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 0.53% Rhenman & Partners Asset Management AB 3Y 7Y 0.45% First Turn Management, LLC 0.4%
← Back to STEMPOINT CAPITAL LP Holdings